Study to Evaluate the Effect of the Coadministration of SCH 497079 (a Histamine 3 [H3] Receptor Antagonist) Plus Desloratadine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis Who Have Been Exposed to Pollen in the Vienna Challenge Chamber (VCC)

Woman and Man

| Country :
| organs :
| Specialty :

Extract

The primary objective of this study is to evaluate the effect on nasal congestion of a maximally tolerated dose of SCH 497079, when taken in combination with DL 5 mg (identified in Phase 1 studies), in subjects with seasonal allergic rhinitis (SAR) who have been exposed to pollen in the VCC. This objective will be accomplished by comparison of the effect on nasal congestion, over the 7.5 hour observation period, of the coadministration of DL 5 mg and SCH 497079 100 mg with that of DL 5 mg taken alone.

Inclusion criteria

Seasonal Allergic Rhinitis

Kusajili – Clinical trials directory

Study to Evaluate the Effect of the Coadministration of SCH 497079 (a Histamine 3 [H3] Receptor Antagonist) Plus Desloratadine on Nasal Congestion in Subjects With Seasonal Allergic Rhinitis Who Have ...